Bim-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Yuan, Zhu ^a   Wang, Fang ^a   Zhao, Zhiwei ^a   Zhao, Xinyu ^a   Qiu, Ji ^a   Nie, Chunlai ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARSENIC TRIOXIDE; BIM PROTEIN; CASPASE 3; CASPASE 9; CISPLATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FKHRL1; AKT1 PROTEIN, HUMAN; APOPTOSIS REGULATORY PROTEIN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; OVARY CANCER; POSITIVE FEEDBACK; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; CELL SURVIVAL; DRUG EFFECT; GENETICS; IMMUNOBLOTTING; METABOLISM; OVARY TUMOR; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARSENICALS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE SILENCING; HUMANS; IMMUNOBLOTTING; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; OXIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 79957851071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020586     Document Type: Article

References (55)

1. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, et al. (2005) Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68: 293-298.
2. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, et al. (2003) AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 278: 23432-23440.
3. Ozols RF, Young RC, (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12: 21-30.
4. Douer D, Tallman MS, (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23: 2396-2410.
5. Cohen MH, Hirschfeld S, Flamm HS, Ibrahim A, Johnson JR, et al. (2001) Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6: 4-11.
6. Zhang N, Wu ZM, McGowan E, Shi J, Hong ZB, et al. (2009) Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: Therapeutic potential for ovarian cancer. Cancer Sci.
7. Du YH, Ho PC, (2001) Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and-resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 47: 481-490.
8. Bornstein J, Sagi S, Haj A, Harroch J, Fares F, (2005) Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecol Oncol 99: 726-729.
9. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, et al. (2000) Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964.
10. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, et al. (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088.
11. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA, (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 88: 4171-4175.
12. Asselin E, Mills GB, Tsang BK, (2001) XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61: 1862-1868.
13. Yang X, Fraser M, Moll UM, Basak A, Tsang BK, (2006) Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136.
14. Brancolini C, (2008) Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated? Curr Mol Pharmacol 1: 24-37.
15. Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, et al. (2003) Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res 63: 312-318.
16. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, et al. (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295.
17. Nakano K, Vousden KH, (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7: 683-694.
18. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, et al. (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038.
19. Qi XJ, Wildey GM, Howe PH, (2006) Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823.
20. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17: 384-395.
21. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, et al. (2000) The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 157: 449-461.
22. Puthalakath H, Huang DC, O'Reilly LA, King SM, Strasser A, (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3: 287-296.
23. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
24. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, et al. (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707.
25. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C, (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998.
26. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868.
27. del PL, Gonzalez-Garcia M, Page C, Herrera R, Nunez G, (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
28. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, et al. (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321.
29. Sunters A, Fernandez de MS, Stahl M, Brosens JJ, Zoumpoulidou G, et al. (2003) FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805.
30. Gilley J, Coffer PJ, Ham J, (2003) FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162: 613-622.
31. Tacka KA, Szalda D, Souid AK, Goodisman J, Dabrowiak JC, (2004) Experimental and theoretical studies on the pharmacodynamics of cisplatin in jurkat cells. Chem Res Toxicol 17: 1434-1444.
32. Morales AA, Gutman D, Lee KP, Boise LH, (2008) BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 111: 5152-5162.
33. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ, (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204.
34. Mann KK, Colombo M, Miller WH Jr, (2008) Arsenic trioxide decreases AKT protein in a caspase-dependent manner. Mol Cancer Ther 7: 1680-1687.
35. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125-137.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
37. Copp J, Manning G, Hunter T, (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 69: 1821-1827.
38. Putcha GV, Le S, Frank S, Besirli CG, Clark K, et al. (2003) JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 38: 899-914.
39. Liu W, Akhand AA, Takeda K, Kawamoto Y, Itoigawa M, et al. (2003) Protein phosphatase 2A-linked and-unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. Cell Death Differ 10: 772-781.
40. Santoro MF, Annand RR, Robertson MM, Peng YW, Brady MJ, et al. (1998) Regulation of protein phosphatase 2A activity by caspase-3 during apoptosis. J Biol Chem 273: 13119-13128.
41. Davison K, Mann KK, Waxman S, Miller WH Jr, (2004) JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103: 3496-3502.
42. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, et al. (2001) Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron 29: 615-628.
43. Lei K, Davis RJ, (2003) JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 100: 2432-2437.
44. Schwabe RF, Uchinami H, Qian T, Bennett BL, Lemasters JJ, et al. (2004) Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. FASEB J 18: 720-722.
45. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J, (2001) Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29: 629-643.
46. Hennigan RF, Stambrook PJ, (2001) Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. Mol Biol Cell 12: 2352-2363.
47. Helm CW, States JC, (2009) Enhancing the efficacy of cisplatin in ovarian cancer treatment- could arsenic have a role. J Ovarian Res 2: 2.
48. Ramos AM, Fernandez C, Amran D, Sancho P, de BE, et al. (2005) Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 105: 4013-4020.
49. Luo J, Manning BD, Cantley LC, (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257-262.
50. Fraser M, Bai T, Tsang BK, (2008) Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122: 534-546.
51. Redondo-Munoz J, Escobar-Diaz E, Hernandez Del CM, Pandiella A, Terol MJ, et al. (2010) Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 16: 4382-4391.
52. Biswas SC, Shi Y, Vonsattel JP, Leung CL, Troy CM, et al. (2007) Bim is elevated in Alzheimer's disease neurons and is required for beta-amyloid-induced neuronal apoptosis. J Neurosci 27: 893-900.
53. Simonin K, Brotin E, Dufort S, Dutoit S, Goux D, et al. (2009) Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells. Mol Cancer Ther 8: 3162-3170.
54. Nie C, Tian C, Zhao L, Petit PX, Mehrpour M, et al. (2008) Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J Biol Chem 283: 15359-15369.
55. Xin M, Deng X, (2005) Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 280: 10781-10789.